Investor Relations

Stock Quote - Ticker Tape

 

Annual Meeting

  o Directions to CEL-SCI's Annual Meeting  
       

SEC Filings

  o View CEL-SCI's SEC Filings  
       

CEL-SCI Presentations & Interviews

  February 2016
NEW CLIP Geert Kersten as a featured guest on Fox Business' Making Money with Charles Payne

 
  January 2016
NEW INTERVIEW Interview with Dr. Eyal Talor, Chief Scientific Officer

 
  January 2016
Geert Kersten at the Noble Financial Capital Markets' 12th Annual Investor Conference

 

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o All Press Releases  
 
  DECEMBER 2, 2016
NEW STORY CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants
  NOVEMBER 21, 2016
NEW STORY CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial
  NOVEMBER 14, 2016
NEW STORY CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis
  OCTOBER 21, 2016
NEW STORY CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial
  SEPTEMBER 26, 2016
NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study
  SEPTEMBER 2, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial
  AUGUST 29, 2016
NEW STORY CEL-SCI Announces the Closing of its $5 Million Registered Direct Offering
  AUGUST 10, 2016
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results
  AUGUST 1, 2016
CEL-SCI Reports Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial
  JULY 11, 2016
CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com